4/25
08:01 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
4/23
08:40 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
4/23
08:20 am
ganx
Rating for GANX
Medium
Report
Rating for GANX
4/23
08:20 am
ganx
Rating for GANX
Medium
Report
Rating for GANX
4/1
08:08 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
3/27
08:09 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
3/27
04:36 am
ganx
Rating for GANX
Medium
Report
Rating for GANX